Altamira Therapeutics (CYTO) Registration Filing summary

Company overview and business model

• Preclinical-stage biopharmaceutical company focused on peptide-based nanoparticle technologies for RNA delivery to extrahepatic tissues, with proprietary OligoPhore™ and Semaphore™ platforms.

• Two flagship siRNA programs, AM-401 (KRAS-driven cancer) and AM-411 (rheumatoid arthritis), are in preclinical development beyond in vivo proof of concept.

• The delivery platform is also available for mRNA and other RNA modalities, with out-licensing to pharma and biotech partners.

• Recent strategic repositioning includes spinning off a majority stake in Altamira Medica AG (Bentrio® nasal spray) and plans to divest or partner other non-core programs.

Financial performance and metrics

• As of December 31, 2023, net tangible book value was $0.05 per share; pro forma as adjusted after the offering, net tangible book value is estimated at $0.80 per share.

• Pro forma as adjusted capitalization post-offering: CHF 8.7 million in shareholders' equity and CHF 12.3 million in total capitalization.

• Company has incurred recurring losses and negative cash flows from operations since inception and expects continued losses due to R&D costs.

• Total cash need for 2024 is projected at CHF 5.0 to 6.0 million, prior to any proceeds from this offering.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.2 million (assuming full sale and exercise of Pre-Funded Warrants, no exercise of other warrants), with actual proceeds potentially lower due to the best efforts structure.

• Proceeds intended for working capital and general corporate purposes; management retains broad discretion over allocation.

• Pending use, proceeds will be invested in short-term, investment-grade, interest-bearing instruments and U.S. government securities.